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1. Introduction
The success of coronary artery bypass grafting (CABG) surgery mainly depends on the pa‐
tency of graft vessels. The predominant mechanism of early graft failure after coronary sur‐
gery is associated with antiplatelet treatment using drungs such as acetylsalicylic acid
(ASA). Prevention using oral ASA in the early postoperative phase in patients with vascular
disease is associated with a 25% to 44% reduction in adverse cardiovascular events (1; 2).
Daily ASA doses ranging between 75-1200mg can similarly reduce fatal and nonfatal events
(2; 3), although studies directly comparing lower and higher doses with regard to clinical
outcomes in the CABG setting have been lacking [4].
2. Clinical ASA resistance
The antithrombotic effect of ASA has been primarily attributed to the irreversible blockade
of the cyclooxygenase- 1 (COX-1) enzyme in platelets that leads to attenuation in the pro‐
duction of an important platelet agonist, thromboxane A2 TXA2 (1; 2). ASA irreversibly in‐
hibits cycloxygenase-1 by acetylating a serine residue at position 529, thereby preventing the
conversion of arachidonic acid to unstable prostaglandine intermediate PGH2, which is con‐
verted to thromboxane TxA2, a potent vasoconstrictor and platelet agonist [22]. The finding
that a considerable number of patients show an impaired antiplatelet effect of ASA in CAD
patients, eminently after CABG threw new light into the discussion concerning poor paten‐
cy rates of bypass grafts: the early period after CABG shows a coincidence of an increased
risk for bypass thrombosis (amongst others, due to platelet activation and endothelial cell
disruption of the graft) and an increased prevalence of ASA resistance [5]. In recent years,
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an increasing number of reports about ASA resistance have led to a growing concern among
clinicians and patients about the efficacy of ASA treatment (6; 7; 8; 9), although one study
group could not reveal any ASA resistance after CABG [10]. ASA resistance can be defined
clinically as an ischemic event while on ASA therapy. Various studies have evaluated the
antiplatelet effect of ASA therapy and have reported the prevalence of ASA resistance 0.4% -
35% of cardiovascular [11, 18] and 5 - 65% of stroke patients [19, 20].
ASA failure has been attributed to many causes, including insufficient dosage, reduced ab‐
sorption or increased metabolism, diabetes mellitus, genes polymorphisms, cell-cell and
drug-drug interactions and poor compliance [12]. Recent findings have suggested that the
pyrazolinone analgesic metamizol, ibuprofen and other nonsteroidal analgesic anti-inflam‐
matory drugs, but not diclofenac, may prevent the irreversible inhibition of platelet throm‐
boxane formation by ASA [15]. The variation suggests about many more treatment failures
with ASA therapy (including incompliance of patients) can be explained by a reduced anti‐
platelet effect for pharmacological reasons Table 1.
Drug-related ASA / Clopidogrel resistance
• Incompliance (23)
• Pharmacokinetics / Pharmacodynamics
• Insufficient bioavailability (low dose-effect relationship)
• Prevention of binding to the Ser529 by other NSAID (Ibuprofen, Indomethacin, Naproxen)
• Exogenous toxins (diabetes mellitus, smoking)
• Impaired sensitivity of platelet COX-1 (CABG)
• Gene polymorphism(s) (COX-1, COX-2, Thromboxan-A2-synthase, Glycoprotein Ia / IIb-, -Ib / V / IX and IIb / IIIa
receptor, Collagen, v.-Willebrand factor and factor VIII)
• Alternative metabolism of thromboxan-A2-biosynthesis (ASA resistance)
• Changing of enteral resoption and biotransformation (Clopidogrel resistance)
Disease-relatedASA / Clopidogrel resistance
• Platelet hyperreactivity due to ASA-insensitive mechanisms
• Changes in the collagen receptor
• Platelet “sensitizing” by Isoprostanes
Table 1. Mechanisms of ASA / Clopidogrel resistance
3. ASA response tests
The common using tests platelet function analyzer (PFA-100TM) closure times (CT); turbidi‐
metric platelet aggregation (TPA) and impedance platelet aggregation (IPA) depending of
platelet and leukocyte counts, Hb, fibrinogen and von Willebrand factor collagen binding
assay (VWF:CBA), the best valid laboratory procedure was not been determinate to screen
for ASA or clopidogrel resistance. One of the studies on on-pump CABG patients agrees
with previous findings suggesting that different platelet function assays that are suitable for
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detecting ASA resistance can not be used interchangeably. Simple linear regression analysis
revealed significant association among CEPI-CT, AA TPA and AA IPA and collagen IPA
Table 2 [14]. In the majority of cases AA IPA (impedance platelet aggregation induced by
arachidonic acid) [16, 17] and ADP-induced platelet aggregation [4] were utilized.
AATPA
Collagen
AAIPA
Collagen
TPA IPA
CEPI-CT
r=0,49*
NS
r=0,35 r=0,31
p<0,0001 p<0,0001 p=0001
AATPA
r=0,38* r=0,43* r=0,28
p<0,0001 p<0,0001 p=0,0006
Collagen TPA NS
r=0,22
p=0,006
AAIPA
r=0,52
p<0,0001
*confirmed by multiple regression analysis
CEPI-CT, collagen/epinephrine closure times; TPA, turbidimetric platelet aggregation; AATPA, turbidimetric platelet
aggregation induced by arachidonic acid; collagen TPA, turbidimetric platelet aggregation induced by collagen; IPA,
impedance platelet aggregation; AAIPA, impedance platelet aggregation induced by arachidonic acid; collagen IPA,
impedance platelet aggregation induced by collagen.
Table 2. Linear regression analysis (Spearman rank correlation coefficients, levels of significance (P<0.01)) determined
in 42 CABG patients before, 1h and 24 h after 300 mg of aspirin intravenously (n=126)
The clean comparison between both different procedures of CABG: on- and off-pump sur‐
gery is unperformed, the role of using extracorporeal circulation as potential destroyer of
cell components for ASA Response uncertain. ASA resistence is a transient phenomenon
during the early postoperatively period in approximately 30% of OPCAB patients, whereby
the ASA response was revered by 6 months [16, 17].
The new age antiplatelet therapy with clopidogrel, prasugrel or ticagrelor seems be effective
in most cardiology diseases (Platelet Inhibition and Patient Outcomes = PLATO Study) like
acute coronary syndrome (ACS), unstable angina pectoris, myocardial infarction (non-STE‐
MI or STEMI) with non- and invasive procedures [13], however is not standard medication
for patients after CABG procedure like ASA. Clopidogrel (75mg/day) is a prodrug, which
needs to be metabolized in the liver to active metabolites catalysed by Cytochrom-P450-
Oxygenase CYP 3A4 and 3A5, which irreversibly inactivate the platelet ADP receptor P2Y12.
Different to ASA clopidogrel does to influent the thienopyridins not cyclooxygenase and
thromboxan formation. Platelet inhibition in patients group with response to clopidogrel
was enhanced by switching to ticagrelol therapy and all clopidogrel. A few studies have re‐
vealed important individual heterogeneity in platelet response to clopidogrel in patients
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with stable coronary disease, but the clinical significance of this phenomenon has not yet
been investigated. Matetzky showed in his study that in 15 out of 60 consecutive patients
STEMI (25%) were resistant to clopidogrel and subsequently were at increased risk of recur‐
rent cardiovascular events in a 6-month follow-up [24].
Non-Responders and Responders treated with ticagrelor will have platelet reactivity below
the cut points associated with ischemic risk in the RESPOND Study [4]. Their resistance in
cardiac surgery after using of extracorporeal circulation (on-pump) or without (off pump) is
unidentified.
Regarding the PLATO trials (Platelet Inhibition and Patient Outcome by ticagrelol) under‐
went CABG endpoints were a non-significant reduction of the primary endpoint like total
major bleeding [HR: 0.84 (95% CI = 0.60–1.16), p = 0.29], significant reduction of CV death
[HR: 0.52 (95% CI = 0.32–0.85)] and all-cause death [HR: 0.49 (95%CI = 0.32– 0.77)] [13].
CABG-related major bleedings according to PLATO or TIMI bleeding definitions were ob‐
served very commonly during CABG.
4. Conclusion
Antiplatelet therapy with ASA is the cornerstone of treatment in coronary artery disease pa‐
tients especiallity after CABG surgery. The question of ASA resistence can be defined clini‐
cally as an ischaemic even while on ASA treatment daily. Laboratory assays of ASA
response are surrogate measures as platelet aggregation inhibitor in vitro does not coinci‐
dentally translate into prevention of thrombosis in vivo, however the tests are not compari‐
bale among themself. Clinical studies are needed to discover the optimal dosing and the
clinical significance of laboratory aspirin resistance for sufficiency of graft function.
Abbreviations
CABG=coronary artery bypass grafting, ASA=acetylsalicylic acid, CAD = coronary artery
disease,mg=milligram, COX-1=cyclooxygenase-1, OPCAB=off-pump coronary artery by‐
pass, TXA2 = thromboxane A2, STEMI=ST segment elevation myocardial infarction
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